Skip to content
value.today

Savara Inc.: financial analysis

Ratios worked out from 10 fiscal years of Savara Inc.'s statements, compared with 665 companies in Biotechnology.

Return on equity, 2025
-63.5%
Biotechnology: -61.0%
Debt to equity, 2025
0.15×
Biotechnology: 0.26×

Savara Inc. scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median5.4×Price to book 5.4× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-9.2%Free cash flow is -9.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.53 vs -0.48Diluted EPS -0.53 in fiscal 2025 against -0.48 the year before (report's currency).
    • ✗Net income higher than five years earlier-$119 M-$119 M in fiscal 2025 against -$50 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$119 MNet income -$119 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-63.5%-63.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 4
    • ✓Short-term assets cover short-term liabilities11.8×Current ratio 11.84 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.15 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $3 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year12.2%Diluted shares up 12.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • More cash than debt: net cash of $3 million.

Worth a look

  • Net loss of $119 million, the 16th loss-making year in a row.
  • Free cash flow was negative: -$101 million.
  • The share count rose 12.2% in the year.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

2of 7(2 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsyes
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

Savara Inc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Return on equity-63.5%-61.5%-44.1%-30.2%-41.2%-61.0%48%
Return on assets-51.0%-49.1%-34.5%-24.1%-31.4%-44.4%45%

Financial strength#

Savara Inc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity0.15×0.16×0.19×0.24×0.18×0.26×59%
Net debt$-3 M$11 M$-0 M$-26 M$-8 M$-16 M39%
Interest cover—————-22.77×—
Current ratio11.84×13.73×15.66×21.97×11.26×4.39×83%
Equity share of assets80.2%80.5%79.1%77.1%81.8%64.7%70%

Cash#

Savara Inc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$-101 M$-89 M$-51 M$-35 M$-40 M$-40 M26%

Shareholder returns#

Savara Inc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Change in share count12.2%20.0%8.1%14.1%—17.3%58%

How each figure is worked out#

Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Change in share count
Diluted shares against the year before. Negative: fewer shares.

Source: Savara Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Savara Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Savara Inc.